6 completed, 2 terminated. 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 2 |
| Phase 3 | 1 | Completed 1 |
Follow Epilepsy, Reflex: new trials by email Literature Review of Epilepsy, Reflex trials Research Report on Epilepsy, Reflex
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy Placebo, E2082 - Photosensitive Epilepsy | Phase 2 | Terminated | Eisai Inc. | 8 | 2018-10-31 | 2020-09-28 |
| A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy Placebo, E2730 - Photosensitive Epilepsy | Phase 2 | Terminated | Eisai Inc. | 6 | 2018-07-27 | 2022-05-04 |
| Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint BRV vs LEV in randomized double blinded, crossover fashion - Photosensitive Epilepsy | Phase 2 / Phase 3 | Completed | Rosenfeld, William E., M.D. | 16 | 2018-06-01 | 2019-03-26 |
| A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients ACT-709478 for oral use, Placebo - Photosensitive Epilepsy | Phase 2 | Completed | Idorsia Pharmaceuticals Ltd. | 5 | 2017-10-06 | 2018-08-31 |
| PF-06372865 in Subjects With Photosensitive Epilepsy PF-06372865, Placebo, Lorazepam - Reflex Epilepsy, Photosensitive | Phase 2 | Completed | Pfizer | 7 | 2015-12-16 | 2018-03-14 |
| Photosensitivity Proof of Concept Trial carbamazepine 400mg, levetiracetam 1000mg - Photosensitive Epilepsy | Phase 2 | Completed | The Epilepsy Study Consortium | 6 | 2009-05-01 | 2012-03-05 |
| Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy BGG492, Placebo - Photosensitive Epilepsy | Phase 2 | Completed | Novartis Pharmaceuticals | 13 | 2008-10-01 | 2016-09-23 |
| A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy JNJ-26489112, Placebo - Photosensitive Epilepsy | Phase 2 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 12 | 2007-10-01 | 2012-04-05 |
Epilepsy (4) · Seizures (3) · Photosensitivity Disorders (1)
Brain Diseases (8) · Central Nervous System Diseases (8) · Nervous System Diseases (8) · Epilepsy (4) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
ACT-709478 (1) · Carbamazepine (1) · Levetiracetam (1) · Lorazepam (1) · N-((6-chloro-2,3-dihydrobenzo(1,4)dioxin-2-yl)methyl)sulfamide (1) · PF-06372865 (1) · selurampanel (1)
Eisai Inc. (2) · Idorsia Pharmaceuticals Ltd. (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Rosenfeld, William E., M.D. (1) · The Epilepsy Study Consortium (1)
United States (5) · Germany (2) · France (1)
Jacqueline French, M.D. (1) · William E Rosenfeld, M.D. (1)